These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38689436)

  • 1. 68 Ga-DOTATOC Pictorial Essay of Various Recurrent Meningiomas Rejected for Treatment With 177 Lu-DOTATATE : Is There a Place for Another Theranostic Examination?
    Moreau A; Maureille A; Kryza D
    Clin Nucl Med; 2024 Jul; 49(7):655-658. PubMed ID: 38689436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
    Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
    Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.
    Severi S; Grassi I; Bongiovanni A; Nicolini S; Marini I; Arpa D; Ranallo N; Azzali I; Di Iorio V; Sarnelli A; Manuela M; Amadori E; Fabbri L; Bartolini D; Tosatto L; Di Meco F; Gurrieri L; Riva N; Calabro L; Matteucci F; Paganelli G; Sansovini M
    J Nucl Med; 2024 Sep; 65(9):1409-1415. PubMed ID: 39142827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
    Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI.
    Afshar-Oromieh A; Giesel FL; Linhart HG; Haberkorn U; Haufe S; Combs SE; Podlesek D; Eisenhut M; Kratochwil C
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1409-15. PubMed ID: 22669255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prospective Registry Study of
    Perlow HK; Nalin AP; Handley D; Gokun Y; Blakaj DM; Beyer SJ; Thomas EM; Raval RR; Boulter D; Kleefisch C; Bovi J; Chen WC; Braunstein SE; Raleigh DR; Knisely JPS; Ivanidze J; Palmer JD
    Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):979-985. PubMed ID: 37871886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication.
    Dressen MS; Muthukrishnan A; Tragon TR; Lieberman FS; Mountz JM
    Clin Nucl Med; 2019 Jan; 44(1):e26-e27. PubMed ID: 30371576
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Kowalski ES; Khairnar R; Gryaznov AA; Kesari V; Koroulakis A; Raghavan P; Chen W; Woodworth G; Mishra M
    Radiat Oncol; 2021 Aug; 16(1):151. PubMed ID: 34399805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.
    Milker-Zabel S; Zabel-du Bois A; Henze M; Huber P; Schulz-Ertner D; Hoess A; Haberkorn U; Debus J
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):222-7. PubMed ID: 16488553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of
    Stade F; Dittmar JO; Jäkel O; Kratochwil C; Haberkorn U; Debus J; Combs SE
    Radiat Oncol; 2018 Apr; 13(1):58. PubMed ID: 29606149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence pattern analysis after [
    Zollner B; Ganswindt U; Maihöfer C; Corradini S; Albert NL; Schichor C; Belka C; Niyazi M
    Radiat Oncol; 2018 Jun; 13(1):110. PubMed ID: 29898747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE.
    Pirisino R; Filippi L; D'Agostini A; Bagni O
    Clin Nucl Med; 2022 Nov; 47(11):e692-e695. PubMed ID: 35695716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice.
    Soto-Montenegro ML; Peña-Zalbidea S; Mateos-Pérez JM; Oteo M; Romero E; Morcillo MÁ; Desco M
    PLoS One; 2014; 9(11):e111624. PubMed ID: 25369268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue.
    Rachinger W; Stoecklein VM; Terpolilli NA; Haug AR; Ertl L; Pöschl J; Schüller U; Schichor C; Thon N; Tonn JC
    J Nucl Med; 2015 Mar; 56(3):347-53. PubMed ID: 25635133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A radiomic- and dosiomic-based machine learning regression model for pretreatment planning in
    Plachouris D; Eleftheriadis V; Nanos T; Papathanasiou N; Sarrut D; Papadimitroulas P; Savvidis G; Vergnaud L; Salvadori J; Imperiale A; Visvikis D; Hazle JD; Kagadis GC
    Med Phys; 2023 Nov; 50(11):7222-7235. PubMed ID: 37722718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
    Kurz SC; Zan E; Cordova C; Troxel AB; Barbaro M; Silverman JS; Snuderl M; Zagzag D; Kondziolka D; Golfinos JG; Chi AS; Sulman EP
    Clin Cancer Res; 2024 Feb; 30(4):680-686. PubMed ID: 38048045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using 68 Ga-DOTATATE PET for Postoperative Radiosurgery and Radiotherapy Planning in Patients With Meningioma: A Case Series.
    Hintz EB; Park DJ; Ma D; Viswanatha SD; Rini JN; Schulder M; Goenka A
    Neurosurgery; 2023 Jul; 93(1):95-101. PubMed ID: 36722951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gallium-68 DOTATATE PET in the Evaluation of Intracranial Meningiomas.
    Ivanidze J; Roytman M; Lin E; Magge RS; Pisapia DJ; Liechty B; Karakatsanis N; Ramakrishna R; Knisely J; Schwartz TH; Osborne JR; Pannullo SC
    J Neuroimaging; 2019 Sep; 29(5):650-656. PubMed ID: 31107591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.